DK1506041T3 - Inbandronsyre til behandling og forebyggelse af osteoporose - Google Patents

Inbandronsyre til behandling og forebyggelse af osteoporose

Info

Publication number
DK1506041T3
DK1506041T3 DK03722591T DK03722591T DK1506041T3 DK 1506041 T3 DK1506041 T3 DK 1506041T3 DK 03722591 T DK03722591 T DK 03722591T DK 03722591 T DK03722591 T DK 03722591T DK 1506041 T3 DK1506041 T3 DK 1506041T3
Authority
DK
Denmark
Prior art keywords
inbandronic
osteoporosis
prevention
acid
treatment
Prior art date
Application number
DK03722591T
Other languages
English (en)
Inventor
Frieder Bauss
Bernhard Pichler
Stephen Turley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29414669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1506041(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1506041T3 publication Critical patent/DK1506041T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
DK03722591T 2002-05-10 2003-05-02 Inbandronsyre til behandling og forebyggelse af osteoporose DK1506041T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010136 2002-05-10
PCT/EP2003/004629 WO2003095029A1 (en) 2002-05-10 2003-05-02 Bisphosphonic acid for the treatment and prevention of osteoporosis

Publications (1)

Publication Number Publication Date
DK1506041T3 true DK1506041T3 (da) 2008-01-28

Family

ID=29414669

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03722591T DK1506041T3 (da) 2002-05-10 2003-05-02 Inbandronsyre til behandling og forebyggelse af osteoporose
DK07014362.3T DK1880744T3 (da) 2002-05-10 2003-05-02 Bisphosphonsyrer til behandlingen og forebyggelse af osteoporose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07014362.3T DK1880744T3 (da) 2002-05-10 2003-05-02 Bisphosphonsyrer til behandlingen og forebyggelse af osteoporose

Country Status (33)

Country Link
US (5) US7410957B2 (da)
EP (4) EP2308563A1 (da)
JP (5) JP2005522526A (da)
KR (7) KR100642961B1 (da)
CN (2) CN1939314A (da)
AR (2) AR039978A1 (da)
AT (1) ATE376444T1 (da)
AU (2) AU2003229770B2 (da)
BR (1) BR0308901A (da)
CA (2) CA2763775C (da)
CY (2) CY1108105T1 (da)
DE (1) DE60317061T2 (da)
DK (2) DK1506041T3 (da)
EC (1) ECSP045335A (da)
ES (2) ES2532393T3 (da)
GT (1) GT200300107A (da)
HK (1) HK1080409A1 (da)
HR (1) HRP20040906B1 (da)
IL (3) IL164371A0 (da)
MX (1) MXPA04009586A (da)
MY (2) MY140080A (da)
NO (2) NO328734B1 (da)
NZ (2) NZ535705A (da)
PA (1) PA8573101A1 (da)
PE (1) PE20040440A1 (da)
PL (2) PL371346A1 (da)
PT (2) PT1880744E (da)
RU (2) RU2387451C2 (da)
SI (2) SI1506041T1 (da)
TW (1) TWI347188B (da)
UY (1) UY27802A1 (da)
WO (1) WO2003095029A1 (da)
ZA (1) ZA200407950B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
RU2294203C2 (ru) * 2001-12-21 2007-02-27 Дзе Проктер Энд Гэмбл Компани Способ лечения костных нарушений
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
KR100642961B1 (ko) * 2002-05-10 2006-11-10 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
PT1790347E (pt) 2002-12-20 2015-02-05 Hoffmann La Roche Formulação de ibandronato a dose elevada
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
JP4559431B2 (ja) * 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
DK1848727T3 (da) * 2005-02-01 2015-07-20 Hoffmann La Roche Ibandronat polymorf b
LT2662380T (lt) * 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CA2648594C (en) * 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2007242883B2 (en) 2006-04-20 2012-09-27 F. Hoffmann-La Roche Ag Diazepan derivatives modulators of chemokine receptors
AU2007335156A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
NO2459176T3 (da) 2009-07-31 2018-02-24
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN107011380A (zh) * 2016-01-28 2017-08-04 臧伟 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124314A (en) * 1872-03-05 Improvement in preparing paper for buildings
US500937A (en) * 1893-07-04 Conduit railway insulator
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
US4509612A (en) 1982-09-28 1985-04-09 Applied Power Inc. Latch mechanism for a tilt-cab truck
JPS59145179A (ja) 1983-01-11 1984-08-20 Ricoh Co Ltd 補充交換用部品を検知可能にした事務機器
IT1195993B (it) 1984-01-12 1988-11-03 Gentili Ist Spa Forme farmaceutiche a base di difosfonati
DE3428524A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
HU199151B (en) 1987-03-10 1990-01-29 Yamanouchi Pharma Co Ltd Process for producing bis-phosphonic acid derivatives
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
DE3825654A1 (de) * 1988-07-28 1990-02-01 Bosch Gmbh Robert Sicherheitseinrichtung an einer handwerkzeugmaschine
JP2691914B2 (ja) 1988-09-09 1997-12-17 株式会社リコー 画像形成装置
US5018651A (en) 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
JP2985205B2 (ja) 1990-01-25 1999-11-29 ミノルタ株式会社 画像形成装置
JPH03226767A (ja) 1990-01-31 1991-10-07 Minolta Camera Co Ltd 画像形成装置管理システム
US5335048A (en) 1990-01-30 1994-08-02 Minolta Camera Kabushiki Kaisha Efficient control system of image forming apparatus
US5356887A (en) 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
JPH04151765A (ja) 1990-10-16 1992-05-25 Fujitsu Ltd ファクシミリ装置の消耗品自動発注方式
ES2149781T3 (es) * 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
SK74594A3 (en) 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
JPH05224479A (ja) 1992-02-10 1993-09-03 Toshiba Corp 画像形成装置
TW237386B (da) 1992-04-15 1995-01-01 Ciba Geigy
WO1994000129A1 (en) 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Use of phosphonates for the treatment of osteoporosis
JPH06111039A (ja) 1992-09-25 1994-04-22 Toray Ind Inc 光学読み取り識別マークの記録方法
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JPH06250802A (ja) 1993-02-22 1994-09-09 Ricoh Co Ltd プリンタ
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JPH07239825A (ja) 1994-02-28 1995-09-12 Canon Inc 状態通報方法およびそれを用いたネットワークシステム
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
JPH07325514A (ja) 1994-05-30 1995-12-12 Ricoh Co Ltd サプライ発注システム
JPH08152825A (ja) 1994-11-30 1996-06-11 Mita Ind Co Ltd 画像形成装置の管理システム
JPH08152814A (ja) 1994-11-30 1996-06-11 Mita Ind Co Ltd 画像形成装置の管理システム
FR2727629A1 (fr) 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
JP3261900B2 (ja) 1994-12-13 2002-03-04 村田機械株式会社 ファクシミリ装置
DE69534923T2 (de) 1994-12-28 2006-11-23 Gador S.A. Anabolische zubereitung für knochenmasse enthaltend olpadronat
JPH08211792A (ja) 1995-02-03 1996-08-20 Mita Ind Co Ltd 画像形成装置の管理システム
US20010051616A1 (en) 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
CA2212996A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of non-vertebral bone fractures
JPH08315052A (ja) 1995-05-18 1996-11-29 Ricoh Co Ltd 自動発注システム
JPH08310007A (ja) 1995-05-19 1996-11-26 Oki Data:Kk シリアルプリンタ
JPH09120238A (ja) 1995-10-25 1997-05-06 Canon Inc 出力装置
JPH09156123A (ja) 1995-12-04 1997-06-17 Brother Ind Ltd プリンタ
JPH09185474A (ja) 1995-12-27 1997-07-15 Fuji Xerox Co Ltd 印刷管理装置
JP3363680B2 (ja) 1995-12-28 2003-01-08 ブラザー工業株式会社 カートリッジの真偽判別方法及びそれを利用した出力装置
JPH09259355A (ja) 1996-03-21 1997-10-03 Oki Electric Ind Co Ltd 梱包された商品の確認処理システム
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5930553A (en) 1997-04-25 1999-07-27 Hewlett-Packard Company Image forming and office automation device consumable with memory
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
US5781405A (en) * 1996-09-30 1998-07-14 Gateway 2000, Inc. Electronic device having rotatably mounted infrared device with a pair of pegs fitting into a pair of holes
US6905701B2 (en) 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US6572874B1 (en) 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
ATE209037T1 (de) * 1997-07-22 2001-12-15 Merck & Co Inc Methoden zur verhinderung von knochenresorption
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
JP3065053B2 (ja) 1998-01-06 2000-07-12 セイコーエプソン株式会社 機器監視システム、ローカル監視装置、統合監視装置、機器監視方法、及び、プログラムを格納したコンピュータ可読媒体
US6432931B1 (en) 1998-06-24 2002-08-13 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6816968B1 (en) 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
IT1303672B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
US6494562B1 (en) 1998-09-03 2002-12-17 Hewlett-Packard Company Method and apparatus for identifying a sales channel
FR2784031B1 (fr) * 1998-10-02 2002-02-01 Sanofi Elf Utilisation de derives de l'acide bisphosphonique pour la preparation d'un medicament destine au traitement des boiteries
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
JP3793023B2 (ja) 1998-12-04 2006-07-05 ロシュ ダイアグノスティックス ゲーエムベーハー 体内プロテーゼの骨統合を促進するためのイバンドロネートの使用
TW442666B (en) * 1998-12-22 2001-06-23 Minolta Co Ltd Zoom lens system
KR100415490B1 (ko) * 1999-01-11 2004-01-24 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. 파워 모스 소자 및 그 제조 방법
ES2211540T3 (es) 1999-04-09 2004-07-16 Karo Bio Ab Receptores de estrogenos y hueso.
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
ES2240106T3 (es) 1999-05-21 2005-10-16 Novartis Ag Uso de acidos bisfosfonicos para el tratamiento de angiogenesis.
US6965411B1 (en) 1999-06-24 2005-11-15 Jones Richard A Remote camera positioner
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US6903836B2 (en) 1999-09-10 2005-06-07 Hewlett-Packard Development Company, L.P. Hard copy cost recovery systems, an apparatus for tracking usage information for a hard copy device, hard copy devices, and a usage accounting method
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6285060B1 (en) * 1999-12-30 2001-09-04 Siliconix Incorporated Barrier accumulation-mode MOSFET
JP2001253827A (ja) 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
US20020004218A1 (en) * 2000-03-31 2002-01-10 Rodan Gideon A. Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
WO2001076592A1 (en) 2000-04-06 2001-10-18 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
AU7410901A (en) 2000-06-20 2002-01-02 Novartis Ag Method of administering bisphosphonates
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
EP1302201A4 (en) 2000-07-17 2007-09-05 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH IMPROVED ABSORBABILITY
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
WO2002058708A1 (en) 2001-01-23 2002-08-01 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
AR034199A1 (es) 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
ATE496624T1 (de) 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
CN1492763B (zh) 2001-03-01 2012-05-23 艾米斯菲尔技术有限公司 用于递送二膦酸盐的组合物
CA2445922A1 (en) 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
US6998678B2 (en) * 2001-05-17 2006-02-14 Infineon Technologies Ag Semiconductor arrangement with a MOS-transistor and a parallel Schottky-diode
WO2003051373A1 (en) 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
RU2294203C2 (ru) * 2001-12-21 2007-02-27 Дзе Проктер Энд Гэмбл Компани Способ лечения костных нарушений
US20050070504A1 (en) 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
DE10207309B4 (de) * 2002-02-21 2015-07-23 Infineon Technologies Ag MOS-Transistoreinrichtung
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
US7186838B2 (en) * 2002-03-13 2007-03-06 Merck & Co., Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
WO2003086415A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
KR100642961B1 (ko) * 2002-05-10 2006-11-10 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
PT1790347E (pt) * 2002-12-20 2015-02-05 Hoffmann La Roche Formulação de ibandronato a dose elevada
GB0424543D0 (en) * 2004-11-05 2004-12-08 Varintelligent Bvi Ltd Driving method for high frame rate display system

Also Published As

Publication number Publication date
HK1080409A1 (en) 2006-04-28
DK1880744T3 (da) 2015-02-09
JP2005522526A (ja) 2005-07-28
MXPA04009586A (es) 2005-01-11
ES2532393T3 (es) 2015-03-26
TWI347188B (en) 2011-08-21
EP1880744B1 (en) 2015-01-21
AR061845A2 (es) 2008-09-24
US7718634B2 (en) 2010-05-18
NO20100477L (no) 2004-10-01
EP1880744A1 (en) 2008-01-23
PT1880744E (pt) 2015-02-13
EP2851105A1 (en) 2015-03-25
BR0308901A (pt) 2005-01-04
ATE376444T1 (de) 2007-11-15
HRP20040906B1 (en) 2013-01-31
JP2013166773A (ja) 2013-08-29
UY27802A1 (es) 2003-11-28
AU2010200438A1 (en) 2010-02-25
AU2003229770B2 (en) 2009-11-05
CY1116233T1 (el) 2017-02-08
CN1646193A (zh) 2005-07-27
EP1506041B1 (en) 2007-10-24
CA2481142A1 (en) 2003-11-20
WO2003095029A1 (en) 2003-11-20
AU2003229770A1 (en) 2003-11-11
ES2294277T3 (es) 2008-04-01
RU2004129324A (ru) 2006-01-27
TW200404553A (en) 2004-04-01
CA2763775C (en) 2014-01-07
PE20040440A1 (es) 2004-08-07
DE60317061D1 (de) 2007-12-06
US7410957B2 (en) 2008-08-12
PA8573101A1 (es) 2004-02-07
JP6067466B2 (ja) 2017-01-25
AU2010200438B2 (en) 2012-02-02
KR100642961B9 (ko) 2021-11-12
MY140080A (en) 2009-11-30
KR20090029312A (ko) 2009-03-20
NO331024B1 (no) 2011-09-12
CY1108105T1 (el) 2014-02-12
SI1506041T1 (sl) 2008-02-29
KR20090106663A (ko) 2009-10-09
US20060166938A1 (en) 2006-07-27
KR20040097267A (ko) 2004-11-17
RU2008103617A (ru) 2009-08-10
CN1939314A (zh) 2007-04-04
DE60317061T2 (de) 2008-07-24
PT1506041E (pt) 2007-12-28
NO328734B1 (no) 2010-05-03
NZ535705A (en) 2007-08-31
GT200300107A (es) 2006-02-23
EP1506041A1 (en) 2005-02-16
IL164371A0 (en) 2005-12-18
JP5837552B2 (ja) 2015-12-24
CN100551377C (zh) 2009-10-21
JP2009132709A (ja) 2009-06-18
MY146809A (en) 2012-09-28
US20030225039A1 (en) 2003-12-04
KR20140021045A (ko) 2014-02-19
ECSP045335A (es) 2004-11-26
US20100197637A1 (en) 2010-08-05
NZ556278A (en) 2009-06-26
US20080249069A1 (en) 2008-10-09
US7192938B2 (en) 2007-03-20
US20050075319A1 (en) 2005-04-07
RU2329809C2 (ru) 2008-07-27
KR20150053811A (ko) 2015-05-18
SI1880744T1 (sl) 2015-04-30
NO20044195L (no) 2004-10-01
PL371346A1 (en) 2005-06-13
EP2308563A1 (en) 2011-04-13
CA2481142C (en) 2012-11-13
HRP20040906A2 (en) 2005-06-30
CA2763775A1 (en) 2003-11-20
KR20060058151A (ko) 2006-05-29
JP2015083592A (ja) 2015-04-30
KR20120065435A (ko) 2012-06-20
KR100642961B1 (ko) 2006-11-10
ZA200407950B (en) 2005-12-28
JP2014058554A (ja) 2014-04-03
RU2387451C2 (ru) 2010-04-27
PL399493A1 (pl) 2012-11-05
IL164371A (en) 2010-11-30
IL205262A (en) 2015-03-31
AR039978A1 (es) 2005-03-09
JP5813911B2 (ja) 2015-11-17

Similar Documents

Publication Publication Date Title
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1427437T3 (da) Oxyntomodulin til forebyggelse eller behandling af overvægt
DK2700309T3 (da) Sammensætninger omfattende et kollagenbiovæv til anvendelse ved behandling af sygdomme og lidelser
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK2508521T4 (da) Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK3199539T3 (da) Hidtil ukendte immunogene sammensætninger til forebyggelse og behandling af meningokoksygdom
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
DK2075000T3 (da) Kombination af azelastin og ciclesonid
DK1563069T3 (da) Sammensætninger og systemer til genregulering
DK1278540T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
DK1206436T3 (da) Retinoider til behandling af emfysem
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1516596T3 (da) Forbedret system til behandling af stress-urinkontinens
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
DK1812797T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af hyperproliferative sygdomme